enGene Holdings Inc.

Healthcare

NASDAQ:ENGN · NASDAQ Capital Market

Market Cap $82.94M Beta -0.29 P/E (TTM) -0.9

$1.62 -1.22%

-$0.02 today

52W Low $1.40High $12.25

Vol 0.45M · Avg 1.55M

EPS (TTM)-$1.82

Biotechnology

Management

Put operating results in leadership context

Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-69.9%

avg -44.3%

ROIC

-61.7%

avg -23.5%

ROA

-53.0%

avg -37.0%

Analysis

ROA is currently the strongest return metric at -53.0% versus its period average of -37.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Management

Key executives, compensation & ownership

Management

Name	Title	Compensation	Tenure	Age	Shares Owned	Ownership %
Ronald H. W. Cooper	President, Chief Executive Officer & Director	$1.21M	—	63	$801,000.00	1.56%
David Ryan Daws	Chief Financial Officer & Head of Business Development	$719,029.00	—	52	$220,000.00	0.43%
Lee G. Giguere	Chief Legal Officer & Corporate Secretary	$605,448.00	—	46	$195,000.00	0.38%
Alex Nichols	Chief Strategy & Operations Officer	$504,442.00	—	40	$195,000.00	0.38%
Anthony T. Cheung	Co-Founder & Chief Scientific Officer	$341,754.00	—	54	$195,000.00	0.38%
Hussein Sweiti	Chief Medical Officer and Head of Research & Development	$257,562.00	—	39	$600,000.00	1.17%
Amy Pott	Chief Global Commercialization Officer	—	—	50	$400,000.00	0.78%
Jill Buck	Chief Development Officer	—	—	52	$195,000.00	0.38%
Joan Connolly	Chief Technology Officer	—	—	56	$195,000.00	0.38%
Matthew Boyd	Chief Regulatory Officer	—	—	52	$195,000.00	0.38%
Tara Place	Senior Vice President of Human Resources	—	—	—	—	—